-+ 0.00%
-+ 0.00%
-+ 0.00%

Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Benzinga·07/01/2026 13:51:10
Listen to the news
Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Outperform and lowers the price target from $60 to $50.